# Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study

> **NCT06890871** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Zhongnan Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Breast Cancer, Metastatic Breast Cancer

## Interventions

- **RADIATION:** Intensity-modulated radiotherapy
- **DRUG:** Immunotherapy Therapy

## Key facts

- **NCT ID:** NCT06890871
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-08-08
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890871, "Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06890871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*